8-K: IN8bio Announces Promising Preclinical Data for Gamma-Delta T Cell Engager Platform at AACR 2025

IN8bio's new gamma-delta T cell engager (gd-TCE) platform demonstrates significant gd T cell expansion and potent anti-cancer activity in preclinical studies, potentially offering a safer alternative to conventional CD3-based approaches.

Summary

• IN8bio announced new preclinical data from its gamma-delta (gd) T cell engager (gd-TCE) platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
• The data showed that IN8bio's gd-TCE platform demonstrated potent and consistent cancer-killing activity across targets in leukemia models.
• The platform avoids the secretion of cytokines that drive the dangerous side effects seen with other TCE based immune therapies.
• The platform's lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), were able to eliminate cancer cells in preclinical studies with minimal release of inflammatory cytokines.
• This potentially offers a lower risk of cytokine release syndrome (CRS) or neurotoxicity, which can impact 60-75% of patients treated with conventional CD3 TCEs.
• INB-619 and INB-633 triggered strong and specific killing of leukemia cells at low picomolar concentrations.
• Both molecules activated and expanded two key gd T cell subsets (Vd1+ and Vd2+).
• The platform has the potential to offer a more scalable and flexible approach to building next-generation immunotherapies because it can drive gd T cell expansion without the need for genetic engineering.
• IN8bio is exploring various disease indications and partnership opportunities for the INB-600 platform.

Sentiment

Score: 8

Explanation: The announcement is positive due to the promising preclinical data and the potential for a safer and more effective cancer immunotherapy. However, the forward-looking statements and associated risks temper the overall sentiment.

Positives

• The gd-TCE platform demonstrates significant gd T cell expansion and activation.
• INB-619 and INB-633 show potent and targeted anti-cancer activity with deep tumor cell depletion in preclinical studies.
• The platform potentially offers a safer alternative to conventional CD3-based approaches, avoiding significant adverse events like cytokine release syndrome (CRS).
• INB-619 and INB-633 triggered strong and specific killing of leukemia cells at low picomolar concentrations.
• The platform can drive gd T cell expansion without the need for genetic engineering, offering a more scalable and flexible approach.
• Targeted B cell elimination (INB-619) highlights potential applications in B cell-driven autoimmune diseases as well as cancer.

Risks

• The company's forward-looking statements are subject to various risks, including those related to clinical trial commencement, patient enrollment, and the ability to meet anticipated deadlines and milestones.
• There are uncertainties inherent in the initiation and completion of preclinical studies and clinical trials.
• IN8bio may be unable to raise additional capital and could be forced to delay, reduce, or terminate certain development programs.
• The company may not realize the intended benefits of its gd-TCE platform or DeltEx platform.
• Preclinical study outcomes may not be predictive of clinical trial results.
• Trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects may arise from the testing or use of IN8bio's product candidates.
• Regulatory approvals to conduct trials or to market products are uncertain.
• IN8bio relies on third parties, including licensors and clinical research organizations.

Future Outlook

IN8bio plans to expand its gd T cell therapeutic pipeline beyond genetically engineered and drug-resistant cellular therapies and is exploring various disease indications and any opportunities for partnership with the INB-600 platform.

Management Comments

• William Ho, CEO and co-founder of IN8bio, commented, 'Our INB-600 TCE platform combines the natural tumor-fighting abilities of gd T cells with bispecific engagers to generate a more precise and powerful way to mobilize the immune system against cancer cells.'
• He added, 'These early results in leukemia models are exciting, and we believe this technology can eventually be applied to other hard-to-treat cancers, and even certain autoimmune diseases.'

Industry Context

The announcement highlights IN8bio's efforts to develop next-generation immunotherapies that are more precise and have fewer side effects than traditional approaches. The focus on gamma-delta T cells and the avoidance of CD3 activation differentiate IN8bio from other companies in the TCE space.

Comparison to Industry Standards

• Conventional CD3 TCEs can cause cytokine release syndrome (CRS) or neurotoxicity in 60-75% of patients.
• IN8bio's gd-TCE platform aims to reduce these side effects by specifically activating only gd T cells.
• The company's approach is differentiated from companies like Amgen (Blincyto) and Kite Pharma (Tecartus) that use CD3-based TCEs.
• IN8bio's platform expands both Vd1+ and Vd2+ subsets, addressing a limitation of earlier gd TCE therapies.

Stakeholder Impact

• Shareholders may benefit from the positive preclinical data and the potential for future partnerships.
• Patients may benefit from a safer and more effective cancer immunotherapy.
• Employees may benefit from the company's growth and expansion.

Next Steps

• IN8bio will present the data at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 30, 2025.
• The company will continue to expand its gd T cell therapeutic pipeline and explore various disease indications and partnership opportunities for the INB-600 platform.

Key Dates

Keywords

IN8bio, gamma-delta T cell, gd-TCE, immunotherapy, cancer, AACR, INB-619, INB-633, leukemia, autoimmune diseases